OncoMatch/Clinical Trials/NCT06028828
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Is NCT06028828 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fludarabine and Melphalan for allogeneic hematopoietic stem cell transplantation.
Treatment: Fludarabine · Melphalan — This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Lab requirements
Kidney function
Serum creatinine clearance ≥ 50 ml/min (Cockroft-Gault formula)
Liver function
Bilirubin ≤ 1.5 mg/dl except for Gilbert's disease. ALT or AST ≤ 200 IU/ml for adults. Conjugated (direct) bilirubin < 2x upper limit of normal.
Cardiac function
Left ventricular ejection fraction ≥ 40%
Adequate major organ system function as demonstrated by: Serum creatinine clearance ≥ 50 ml/min (Cockroft-Gault formula). Bilirubin ≤ 1.5 mg/dl except for Gilbert's disease. ALT or AST ≤ 200 IU/ml for adults. Conjugated (direct) bilirubin < 2x upper limit of normal. Left ventricular ejection fraction ≥ 40%. Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify